What predicts psychiatric symptoms over one year in methamphetamine-induced psychosis
Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study
This will see if social, family, and individual factors predict changes in psychiatric symptoms over one year in adults with methamphetamine-induced psychosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Male |
| Sponsor | Elazığ Mental Health and Diseases Hospital Government |
| Locations | 1 site (Elâzığ, Elâzığ) |
| Trial ID | NCT07459257 on ClinicalTrials.gov |
What this trial studies
This is a one-year longitudinal observational follow-up of adult male patients diagnosed with methamphetamine-induced psychotic disorder who were medication-free for at least one month at entry. Participants were followed monthly with standardized psychometric instruments to record sociodemographic data, treatment adherence, perceived social support, insight, addiction-related clinical variables, and psychotic symptom severity. The study aimed to identify factors associated with relapse-remission patterns and symptom trajectory over time. It was conducted at Elazığ Mental Health and Diseases Hospital using prospective data collection and repeated measures analyses.
Who should consider this trial
Good fit: Adult men aged 18 to under 65 with a DSM-5-TR diagnosis of methamphetamine-induced psychotic disorder who are medication-free for at least one month and able to give informed consent.
Not a fit: People with primary psychiatric diagnoses other than methamphetamine-induced psychosis, significant medical comorbidities listed in the exclusion criteria, alcohol use disorder, or who cannot attend monthly visits (including those outside the recruitment region) are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the findings could help clinicians anticipate relapse and personalize social and treatment supports to reduce symptom persistence.
How similar studies have performed: Most prior work has been cross-sectional or retrospective, so longitudinal prediction of symptom trajectories in this population is limited and this approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* Methamphetamine-Induced Psychotic Disorder (MP) Group:
\*Inclusion Criteria:
* Diagnosis of MP according to DSM-5-TR
* Medication-free for at least one month prior to admission
* Age ≥ 18 years and \<65 years
* Provided informed consent
* Methamphetamine-Induced Psychotic Disorder (MP) Group:
* Exclusion Criteria:
* Hypertension
* Diabetes mellitus
* Chronic kidney disease
* Rheumatoid arthritis
* Systemic lupus erythematosus
* Cardiac illness
* Severe neurological disorders
* Immunological or systemic illness
* Primary psychiatric disorders other than MP
* Alcohol use disorder
Where this trial is running
Elâzığ, Elâzığ
- Elazığ Mental Health and Diseases Hospital — Elâzığ, Elâzığ, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist
- Email: mhorum@hotmail.com
- Phone: +905382207558
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.